CytoMed Therapeutics Limited
1 Commonwealth Lane #08-22
Singapore 149544
March 31, 2023
VIA EDGAR
U.S. SECURITIES AND EXCHANGE COMMISSION
Division of Corporation Finance, Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attention: Tracie Mariner
| Re: | CytoMed Therapeutics Limited |
Registration Statement on Form F-1
Originally Filed November 18, 2022
File No. 333-268456
Dear Ms. Mariner:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, CytoMed Therapeutics Limited (the “Company”) hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 5:00 p.m. on Friday, March 31, 2023, or as soon as thereafter practicable (the “Effective Time”). The Company hereby grants to each of Richard I. Anslow, Esq., Lijia Sanchez, Esq. and Kristina R. Brown, Esq. the authority to communicate to the staff of the U.S. Securities and Exchange Commission one or more requests for any potential deferral of the Effective Time.
| Very truly yours, | |
| /s/ CHOO Chee Kong | |
| CHOO Chee Kong | |
| Director and Chairman |
